摘要
为观察膦甲酸钠抗乙型肝炎病毒 (HBV)的近期疗效 ,将 6 7例慢性乙型肝炎患者随机分为 2组 :治疗组 4 7例 ,在常规保肝治疗的基础上加用膦甲酸钠 ;对照组 2 0例 ,仅用常规保肝药物治疗。治疗前后观察患者肝功能、血清HBVDNA含量、乙肝病毒免疫学标志等的变化。结果显示 ,治疗 2周后 ,治疗组肝功能均有恢复 ;4 7例患者中 4 2例HBVDNA水平下降 ,以第 1周明显 ,第 2周时 10例反跳 ;13例HBVDNA转阴 ,其中 5例在用药 1周后即转阴。30例HBeAg阳性患者中 ,2例出现血清转换 ,1例转为弱阳性。提示膦甲酸钠具有明显和快速的抑制乙肝病毒复制、降低病毒量的作用 ,可作为抗病毒序贯疗法的首程用药或联合用药的选择之一。
To investigate the short term anti HBV efficacy of foscarnet sodium, sixty seven patients with various types of chronic hepatitis B were randomly divided into two groups. The experimental group (47 cases) was assigned to receive foscarnet sodium 3 0g by intravenous infusion twice daily in addition to general liver protective medicine for 15 days. The control group (20 cases) was treated with regular liver protective medicine only. The quantity of HBV DNA was measured with equivalent competitive PCR combining with DNA hybridization quantitative detection technique before and after treatment (once a week). The HBV markers and liver functions were also tested before and after treatment. In antiviral therapy group, the patients with different types of hepatitis B had their liver functions improved. HBV DNA in 13 patients became negative by PCR. Two of HBeAg positive patients became sero converted. Foscarnet sodium can inhibit HBV efficiently and quickly. The replication of HBV DNA can be greatly suppressed in the first week but without significant change in the second week in some cases. Foscarnet can be one of the drugs of choice in a combined therapy or as the initial drug in a sequential therapeutic regime.
出处
《解放军医学杂志》
CAS
CSCD
北大核心
2002年第3期265-267,共3页
Medical Journal of Chinese People's Liberation Army
